Gilead Sciences Inc
NASDAQ: GILD
$83.94
+$0.04 (+0.0%)
Closing Price on September 20, 2024
GILD Articles
Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue...
Published:
Last Updated:
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical...
Published:
Last Updated:
In a recent report, UBS made some significant changes to its Equity Focus list. The analysts look to go a touch more aggressive with the new additions.
Published:
Last Updated:
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Published:
Last Updated:
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.
Published:
Last Updated:
Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on the stock.
Published:
Last Updated:
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion in market cap since August.
Published:
Last Updated:
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Published:
Last Updated:
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
Published:
Last Updated:
It is time to take a look at the 2016 stock buyback kings, those companies that will spend the most buying back their common stock this year alone.
Published:
Last Updated:
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday include Activision Blizzard, Boeing, FireEye, Gilead Sciences, Groupon, Netflix and Pandora Media.
Published:
Last Updated: